AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30782924 — intervention group
Group type: COMPARATOR
Intervention: Hospital treatment for non-complex fractures or dislocations
Number of subjects: 200
Study 30782925 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes (PROs) assessed using validated instruments at baseline, 1, 6, and 12 months follow-up.
Number of subjects: 5000
Study 30782925 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised transthoracic echocardiograms and 6-minute walk tests at baseline and at 1 and 12 months after discharge.
Number of subjects: 5000
Study 30782925 — intervention group
Group type: EXPERIMENTAL
Intervention: Collection of blood and urine samples at baseline, 1 and 12 months follow-up.
Number of subjects: 5000
Study 30782948 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert CT/NG
Number of subjects: 247
Study 30782948 — intervention group
Group type: EXPERIMENTAL
Intervention: OSOM TV
Number of subjects: 247
Study 30782948 — intervention group
Group type: COMPARATOR
Intervention: Anyplex II STI-7 Detection
Number of subjects: 247
Study 30782999 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin (750- to 1,000-mg once-daily dosing)
Number of subjects: 23
Study 30783204 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin mesilate (1.6 mg/m²) in combination with capecitabine (1000 mg/m² twice daily)
Number of subjects: 34
Study 30783888 — intervention group
Group type: EXPERIMENTAL
Intervention: ALLN-177 (7,500 units/meal, 3 times a day)
Number of subjects: 16
Study 30784639 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial-only access (RA)
Number of subjects: 3790
Study 30784639 — intervention group
Group type: COMPARATOR
Intervention: Radial-femoral access (RFA)
Number of subjects: 3790
Study 30784639 — intervention group
Group type: COMPARATOR
Intervention: Femoral-only access
Number of subjects: 3790
Study 30784647 — intervention group
Group type: EXPERIMENTAL
Intervention: Paladin System (angioplasty balloon with integrated embolic protection filter)
Number of subjects: 106
Study 30784680 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified HEART Score and High-Sensitivity Cardiac Troponin
Number of subjects: 0
Study 30784685 — intervention group
Group type: EXPERIMENTAL
Intervention: Micra implantation
Number of subjects: 201
Study 30784691 — intervention group
Group type: EXPERIMENTAL
Intervention: PPG algorithm using a commercially available smartwatch
Number of subjects: 508
Study 30784691 — intervention group
Group type: COMPARATOR
Intervention: Cardiologists' diagnosis by electrocardiography (ECG)
Number of subjects: 508
Study 30785625 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 2215
Study 30785829 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus low-dose ipilimumab (nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks)
Number of subjects: 288
Study 30785829 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus low-dose ipilimumab
Number of subjects: 288
Study 30786000 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral arterial stiffness (AS) defined as an ankle-brachial index (ABI) >1.2
Number of subjects: 264
Study 30786000 — intervention group
Group type: COMPARATOR
Intervention: Normal ABI
Number of subjects: 264
Study 30786000 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral arterial stiffness (AS) with concomitant asymptomatic peripheral arterial disease (aPAD)
Number of subjects: 264
Study 30786000 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral arterial stiffness (AS)
Number of subjects: 264
Study 30786188 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan-hziy (10 mg/kg) administered intravenously on days 1 and 8 of each 21-day cycle until disease progression or unacceptable toxic effects.
Number of subjects: 108
Study 30786996 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective shoulder replacement surgery
Number of subjects: 51895
Study 30787085 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Information Leaflets (PILs) given by physicians along with an oral explanation.
Number of subjects: 324
Study 30787085 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Information Leaflets (PILs) given by physicians.
Number of subjects: 324
Study 30787124 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 treatment
Number of subjects: 0
Study 30787124 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30787176 — intervention group
Group type: EXPERIMENTAL
Intervention: TAS0728, a covalent-binding HER2-selective kinase inhibitor
Number of subjects: 0
Study 30787176 — intervention group
Group type: EXPERIMENTAL
Intervention: TAS0728
Number of subjects: 0
Study 30787625 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab 200 mg SC every 2 weeks
Number of subjects: 0
Study 30787625 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab 40 mg SC every 2 weeks/weekly
Number of subjects: 0
Study 30787641 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (50,000 IU weekly)
Number of subjects: 86
Study 30787641 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (300 mg daily)
Number of subjects: 86
Study 30787641 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Vitamin D3 and Omega-3 fatty acids
Number of subjects: 86
Study 30787641 — intervention group
Group type: COMPARATOR
Intervention: Control (Vitamin D3 alone)
Number of subjects: 86
Study 30787930 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolerogenic dendritic cells
Number of subjects: 0
Study 30787930 — intervention group
Group type: EXPERIMENTAL
Intervention: T-regulatory cells
Number of subjects: 0
Study 30788134 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-administered HIV point-of-care testing (POCT) with pre/post-test counseling and linkage to care plans
Number of subjects: 0
Study 30788134 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-administered HIV point-of-care testing (POCT)
Number of subjects: 0
Study 30788134 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacy-based HIV testing model
Number of subjects: 0
Study 30788134 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based research approach
Number of subjects: 0
Study 30788134 — intervention group
Group type: EXPERIMENTAL
Intervention: Multipronged promotion campaign
Number of subjects: 0
Study 30788134 — intervention group
Group type: EXPERIMENTAL
Intervention: Preliminary costing assessment
Number of subjects: 0
Study 30788136 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditation training
Number of subjects: 0
Study 30788136 — intervention group
Group type: COMPARATOR
Intervention: Music listening (control)
Number of subjects: 0
Study 30788571 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacrocolpopexy (SCP)
Number of subjects: 213
Study 30788571 — intervention group
Group type: COMPARATOR
Intervention: Native Tissue Repair (NTR)
Number of subjects: 213
Study 30788571 — intervention group
Group type: COMPARATOR
Intervention: Vaginal Mesh Repair (VMR)
Number of subjects: 213
Study 30788718 — intervention group
Group type: EXPERIMENTAL
Intervention: Icosapent ethyl 4 g/day
Number of subjects: 702
Study 30788718 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 702
Study 30789648 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Stereotactic Ablative Radiotherapy (SABR) followed by surgery 10 weeks later
Number of subjects: 40
Study 30789827 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week intensive outpatient rehabilitation including memantine and morphine treatment, psychological and physiotherapeutic intervention
Number of subjects: 10
Study 30789827 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week intensive outpatient rehabilitation
Number of subjects: 10
Study 30790030 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal carbon dioxide removal (ECCO)
Number of subjects: 95
Study 30790296 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 30790403 — intervention group
Group type: EXPERIMENTAL
Intervention: AV-1451
Number of subjects: 27
Study 30790403 — intervention group
Group type: COMPARATOR
Intervention: Cognitively normal controls
Number of subjects: 27
Study 30790469 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative gastric radiotherapy (36 Gy in 12 daily fractions)
Number of subjects: 50
Study 30790695 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact-free monitoring of respiratory rates
Number of subjects: 0
Study 30790695 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 30791143 — intervention group
Group type: EXPERIMENTAL
Intervention: MMR/Hib-MenC vaccination
Number of subjects: 311
Study 30791143 — intervention group
Group type: COMPARATOR
Intervention: Control group (MMR/Hib-MenC-naïve)
Number of subjects: 311
Study 30791951 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent breakfast consumption (6 to 7 days/week)
Number of subjects: 6228
Study 30791951 — intervention group
Group type: COMPARATOR
Intervention: Rare breakfast consumption (0 to 2 days/week)
Number of subjects: 6228
Study 30791951 — intervention group
Group type: COMPARATOR
Intervention: Occasional breakfast consumption (3 to 5 days/week)
Number of subjects: 6228
Study 30791951 — intervention group
Group type: COMPARATOR
Intervention: Daily breakfast consumption
Number of subjects: 6228
Study 30792190 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg orally twice daily, pomalidomide 4 mg orally on days 1 to 21, and dexamethasone 40 mg orally on days 1, 8, 15, and 22 of a 28-day cycle
Number of subjects: 120
Study 30792190 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin, pomalidomide, and dexamethasone (ClaPd)
Number of subjects: 120
Study 30792199 — intervention group
Group type: EXPERIMENTAL
Intervention: ADAMTS13 activity
Number of subjects: 0
Study 30792246 — intervention group
Group type: EXPERIMENTAL
Intervention: Active smokers at time of surgery
Number of subjects: 57
Study 30792246 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with high clonality (above 26.8%)
Number of subjects: 57
Study 30792246 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistence of similar TCR repertoire at postoperative endoscopy
Number of subjects: 57
Study 30792246 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with high clonality
Number of subjects: 57
Study 30792246 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonal T cell expansions
Number of subjects: 57
Study 30792251 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment
Number of subjects: 224
Study 30792873 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN)
Number of subjects: 25
Study 30792945 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic risk score (GRS; based on 28 genomic variants)
Number of subjects: 203
Study 30792945 — intervention group
Group type: COMPARATOR
Intervention: Conventional risk score (CRS; based on traditional risk factors)
Number of subjects: 203
Study 30793003 — intervention group
Group type: EXPERIMENTAL
Intervention: Herpes zoster (HZ) patients
Number of subjects: 391
Study 30793003 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with postherpetic neuralgia (PHN)
Number of subjects: 391
Study 30793003 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who developed PHN
Number of subjects: 391
Study 30793242 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative reintervention
Number of subjects: 1955
Study 30793242 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical site infection
Number of subjects: 1955
Study 30793242 — intervention group
Group type: EXPERIMENTAL
Intervention: Open surgery
Number of subjects: 1955
Study 30793242 — intervention group
Group type: EXPERIMENTAL
Intervention: Distant metastasis
Number of subjects: 1955
Study 30793242 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged LOS (> 14 days)
Number of subjects: 1955
Study 30793242 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster analysis results
Number of subjects: 1955
Study 30793351 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-centred inpatient care intervention including systematically applied person-centred assessment, health plans, and persistent PCC.
Number of subjects: 204
Study 30793351 — intervention group
Group type: COMPARATOR
Intervention: Control group (pre-intervention data)
Number of subjects: 204
Study 30793701 — intervention group
Group type: EXPERIMENTAL
Intervention: Drugs associated with drug-induced lupus (DIL)
Number of subjects: 12166
Study 30794033 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced subgroups from empirical data on treatment effectiveness
Number of subjects: 0
Study 30795749 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure therapy
Number of subjects: 60
Study 30795749 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in self-focused attention
Number of subjects: 60
Study 30795749 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in social self-efficacy
Number of subjects: 60
Study 30795749 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated social costs
Number of subjects: 60
Study 30795797 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous mesenchymal stromal cells (MSCs) embedded in tricalcium phosphate
Number of subjects: 11
Study 30795810 — intervention group
Group type: EXPERIMENTAL
Intervention: ActiGraph GT3X+
Number of subjects: 50
Study 30795996 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab (16 mg/kg; administered intravenously weekly for 2 cycles, every 2 weeks for 4 cycles, and every 4 weeks thereafter)
Number of subjects: 36
Study 30795996 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab
Number of subjects: 36
Study 30796032 — intervention group
Group type: EXPERIMENTAL
Intervention: MTI-31 (LXI-15029), a novel mTORC1/mTORC2 inhibitor
Number of subjects: 0
Study 30796032 — intervention group
Group type: EXPERIMENTAL
Intervention: MTI-31 (LXI-15029)
Number of subjects: 0
Study 30796035 — intervention group
Group type: EXPERIMENTAL
Intervention: ADI-PEG20 (36 mg/m weekly) with pemetrexed and cisplatin (ADIPEMCIS)
Number of subjects: 10
Study 30796037 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker assays for assessing EGFR abnormalities
Number of subjects: 0
Study 30796113 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean dietary pattern
Number of subjects: 18429
Study 30796113 — intervention group
Group type: EXPERIMENTAL
Intervention: Western dietary pattern
Number of subjects: 18429
Study 30796113 — intervention group
Group type: EXPERIMENTAL
Intervention: Provegetarian dietary pattern
Number of subjects: 18429
Study 30796119 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-world data collection on MBC management
Number of subjects: 16700
Study 30796119 — intervention group
Group type: EXPERIMENTAL
Intervention: Ancillary research projects
Number of subjects: 16700
Study 30796155 — intervention group
Group type: EXPERIMENTAL
Intervention: Genexol-PM (230 mg/m2) plus cisplatin
Number of subjects: 52
Study 30796299 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine metabolomics analysis during normal pregnancy progression
Number of subjects: 50
Study 30796299 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine metabolomics for early prediction of gestational diabetes mellitus (GDM)
Number of subjects: 50
Study 30796299 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine metabolomics for early prediction of spontaneous abortion (SA)
Number of subjects: 50
Study 30796821 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel with trastuzumab and pertuzumab
Number of subjects: 1436
Study 30796821 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel with trastuzumab and pertuzumab
Number of subjects: 1436
Study 30796821 — intervention group
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel with trastuzumab and pertuzumab
Number of subjects: 1436
Study 30796821 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment (pertuzumab, trastuzumab, and taxane)
Number of subjects: 1436
Study 30796821 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel-containing therapy
Number of subjects: 1436
Study 30796821 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-containing therapy
Number of subjects: 1436
Study 30797139 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine and rituximab (BR) as first-line treatment
Number of subjects: 83
Study 30797141 — intervention group
Group type: EXPERIMENTAL
Intervention: TPF (docetaxel, cisplatin, and fluorouracil)
Number of subjects: 278
Study 30797141 — intervention group
Group type: COMPARATOR
Intervention: PF (cisplatin and fluorouracil)
Number of subjects: 278
Study 30797384 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based brief intervention for parents using cognitive-behavioral (CB) and motivational interviewing (MI) strategies
Number of subjects: 0
Study 30797575 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid prescription and pain management
Number of subjects: 372
Study 30797634 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE527 vaccine with dmLT adjuvant
Number of subjects: 60
Study 30797634 — intervention group
Group type: COMPARATOR
Intervention: Placebo (unimmunized controls)
Number of subjects: 60
Study 30797634 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE527 vaccine without adjuvant
Number of subjects: 60
Study 30797636 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal polysaccharide-based vaccines (PPV and/or PCV/PPV)
Number of subjects: 0
Study 30798615 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP, NT-proBNP, hs-cTnT, hs-cTnI concentrations
Number of subjects: 1538
Study 30798615 — intervention group
Group type: COMPARATOR
Intervention: EGSYS (Evaluation of Guidelines in Syncope Study)
Number of subjects: 1538
Study 30798615 — intervention group
Group type: COMPARATOR
Intervention: Death and major adverse cardiac events at 30 and 720 days
Number of subjects: 1538
Study 30798615 — intervention group
Group type: COMPARATOR
Intervention: ROSE, OESIL, SFSR, CSRS
Number of subjects: 1538
Study 30799546 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild therapeutic hypothermia (MTH) group
Number of subjects: 41
Study 30799546 — intervention group
Group type: COMPARATOR
Intervention: No-MTH group
Number of subjects: 41
Study 30800095 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Weight Support Combined With Treadmill Training
Number of subjects: 0
Study 30800095 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30800421 — intervention group
Group type: EXPERIMENTAL
Intervention: ABX464 150-mg
Number of subjects: 30
Study 30800421 — intervention group
Group type: EXPERIMENTAL
Intervention: ABX464 50-mg
Number of subjects: 30
Study 30800421 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30800562 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipragliflozin 50 mg once-daily
Number of subjects: 175
Study 30800562 — intervention group
Group type: COMPARATOR
Intervention: Ipragliflozin with DPP-4 inhibitor
Number of subjects: 175
Study 30800562 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipragliflozin
Number of subjects: 175
Study 30800637 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroidectomy (surgery)
Number of subjects: 64
Study 30801037 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen combined with amphotericin B and fluconazole
Number of subjects: 0
Study 30801535 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic variant rs2910164 (microRNA MIR146A)
Number of subjects: 2872
Study 30801535 — intervention group
Group type: EXPERIMENTAL
Intervention: Other genetic variants (CTLA and TLR4)
Number of subjects: 2872
Study 30801535 — intervention group
Group type: COMPARATOR
Intervention: 75 common genetic variants
Number of subjects: 2872
Study 30801647 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato-soy juice (0, 1, or 2 cans/day; 163 mL/can; 20.6 mg lycopene, 1.2 mg β-carotene/can) for 24 ± 0.7 days
Number of subjects: 47
Study 30801911 — intervention group
Group type: EXPERIMENTAL
Intervention: BKM120 combined with vemurafenib
Number of subjects: 0
Study 30801911 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 30801984 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity Energy Expenditure (PAEE) in WLM
Number of subjects: 25
Study 30801984 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Daily Energy Expenditure (TDEE) in WLM
Number of subjects: 25
Study 30801989 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily dietary self-monitoring using a Web-based dietary analysis program
Number of subjects: 142
Study 30801989 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring frequency
Number of subjects: 142
Study 30801989 — intervention group
Group type: EXPERIMENTAL
Intervention: Time spent self-monitoring
Number of subjects: 142
Study 30802417 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 30802419 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine (10-20 mg/day)
Number of subjects: 199
Study 30802592 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular aortic repair (EVAR)
Number of subjects: 44
Study 30802592 — intervention group
Group type: COMPARATOR
Intervention: Open surgical repair (OSR)
Number of subjects: 44
Study 30802998 — intervention group
Group type: EXPERIMENTAL
Intervention: VY-AADC01 (8.3 × 10^10 vg/mL) administered bilaterally with gadoteridol using MRI guidance
Number of subjects: 15
Study 30803311 — intervention group
Group type: EXPERIMENTAL
Intervention: High-perceived risk/high-perceived control group
Number of subjects: 30
Study 30803311 — intervention group
Group type: EXPERIMENTAL
Intervention: High-perceived risk/low-perceived control group
Number of subjects: 30
Study 30803311 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-perceived risk/low-perceived control group
Number of subjects: 30
Study 30803311 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-perceived risk/high-perceived control group
Number of subjects: 30
Study 30803705 — intervention group
Group type: EXPERIMENTAL
Intervention: Miransertib at a dose of 5 mg/m
Number of subjects: 0
Study 30803948 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive continuous care intervention (CCI)
Number of subjects: 349
Study 30803948 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 349
Study 30803990 — intervention group
Group type: EXPERIMENTAL
Intervention: Parsaclisib monotherapy (5-45 mg once daily)
Number of subjects: 72
Study 30803997 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-drug interventions for perinatal depression
Number of subjects: 0